Spero Therapeutics, Inc.
SPRO US84833T1034
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -11% | -89% | -16% | -32% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Keutzer Timothy COO |
1.97 USD |
1,695 Sold |
3,339 USD |
28/08/2025 | 28/08/2025 |
| Mahadevia Ankit |
1.97 USD |
6,572 Sold |
12,947 USD |
28/08/2025 | 28/08/2025 |
| Mahadevia Ankit |
1.97 USD |
6,572 Sold |
12,947 USD |
28/08/2025 | 28/08/2025 |
| Shukla Sath CEO |
0.78 USD |
106,408 Sold |
82,998 USD |
03/02/2025 | 05/02/2025 |
| Mahadevia Ankit |
0.78 USD |
55,260 Sold |
43,103 USD |
05/02/2025 | 05/02/2025 |
| Mahadevia Ankit |
0.78 USD |
13,959 Sold |
10,888 USD |
05/02/2025 | 05/02/2025 |
| Keutzer Timothy COO |
0.78 USD |
24,920 Sold |
19,438 USD |
03/02/2025 | 05/02/2025 |
| Keutzer Timothy COO |
0.78 USD |
27,643 Sold |
21,562 USD |
03/02/2025 | 05/02/2025 |
| Shukla Sath CEO |
0.78 USD |
42,786 Sold |
33,373 USD |
03/02/2025 | 05/02/2025 |
| Keutzer Timothy COO |
0.78 USD |
3,974 Sold |
3,100 USD |
03/02/2025 | 05/02/2025 |